🇷🇺 Русская версия | 🇬🇧 English version
Market-entry case study: strategy, unit economics, and financial scenarios
Team: Nikita Tolmachev, Artem Sukhanov, Egor Starikov
Timeline: December 2024
Develop a comprehensive market entry strategy for Ozon Pharm's expansion into Uzbekistan's pharmaceutical market, covering strategy, product, operations, marketing, unit economics, and financial projections.
Our team designed a full-scale expansion plan for entering Uzbekistan's rapidly growing pharma market through generic drug distribution.
- TAM: $1.9B (2023)
- Market growth: 15%+ annually
- Import share: 75% of total market
- Target market share: 1-3% initially
Entry strategy: Partnership with local distributors (minimal capex, faster time-to-market)
Product positioning: High-quality generic drugs at competitive prices (15-18% markup vs. Russian retail)
Competitive advantages:
- Largest generic portfolio in Russia (378M+ packages/year production capacity)
- Strategic location (Samara production facilities enable easy logistics)
- Trusted Russian brand recognition in CIS markets
Distribution channels:
- Major pharmacy chains (Grandpharm, Shohfarm, OXYmed)
- Online platforms (Apteka.uz, Uzum, Wildberries Uzbekistan)
- Hospitals and clinics
- Direct B2B partnerships with distributors
Pricing strategy: Competitor-based + value-based hybrid, targeting middle-income segments
- Average transaction: ₽167.2 (20,398 UZS)
- CAC: ₽11.3 (4.7% of revenue)
- Operating costs: ₽46.5 (12.8% of revenue)
- Profit per unit: ₽21.8 (14% margin)
Industry benchmark: 13.4% average margin — our model exceeds industry standard by 0.6pp
- Revenue: ₽3.22B
- Operating expenses: ₽2.80B
- Net profit: ₽420M annually
- Initial investment: ₽253M (warehouse build-out scenario)
- Payback period: 7-8 months
The financials are scenario-model outputs, not company guidance or realized market performance. Results depend on market-share, pricing, regulatory, logistics, and warehouse assumptions documented in the workbook.
- Market research: analyzed Uzbekistan pharma market dynamics (TAM/SAM/SOM sizing, growth drivers, regulatory landscape)
- Competitive analysis: benchmarked Russian competitors (Materia Medica, Valenta, Nizhpharm) and pricing strategies; conducted Porter's 5 Forces assessment
- Unit economics modeling: built financial model in Excel with revenue/cost structure, calculated unit-level profitability, and validated against industry benchmarks
- Strategic frameworks: contributed to 3C analysis, SWOT, and market entry strategy selection (partnership vs. M&A vs. in-house)
- 3C Analysis (Company, Customers, Competition)
- PESTEL (macro environment)
- Porter's 5 Forces
- SWOT
- Competitor-based pricing
- Value-based pricing
- Cost-based pricing
- Customer Journey Map (CJM)
- Marketing Mix (4P)
- Channel effectiveness analysis (CAC, conversion rates)
- NPV, IRR, payback period
- Unit economics (LTV, CAC, contribution margin)
- Sensitivity analysis
- Financial modeling: MS Excel (DCF, unit economics, P&L projections)
- Presentation: MS PowerPoint
- Research: Open-source market data, regulatory databases, competitor benchmarking
- Final presentation — full strategy deck with analysis and recommendations
- Financial model — unit economics and investment calculations
This is an independent market-entry case based on open-source market information and the assumptions recorded in the financial model. It is not investment advice and was not commissioned or validated by Ozon Pharm.